Takeda’s High-Dose TYK2 Data Could Set It Apart In Psoriasis

 
• By Jessica Merrill
gold medal
Takeda thinks its TYK2 inhibitor could be best in class • Source: Shutterstock

More from Immunological

More from Therapeutic Category